– New clinical trial will assess first-of-its-kind MitraClip™ transcatheter mitral valve repair against current standard of care surgery in a new, expanded patient population – If successful, the REPAIR MR study has potential to expand MitraClip’s current indication (patients at prohibitive risk for surgery) to also include patients at moderate […]
Coronary/Structural Heart
Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD
BETonMACE Results Show 57% Hazard Reduction in Primary MACE for Patients on Apabetalone and New Oral Anti-Diabetic Treatments CALGARY, Alberta, Jan. 13, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) is pleased to announce today additional highly significant findings and clear synergy when apabetalone is combined […]
First Japanese Patients Randomized In Corvia Medical’s REDUCE LAP-HF II Global Clinical Trial For Heart Failure
Pivotal study investigates the Corvia InterAtrial Shunt Device (IASD®) for heart failure TEWKSBURY, Mass., Jan. 13, 2020 /PRNewswire/ — Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced the first Japanese patients were randomized in Toyama and Hyogo under a clinical trial authorization […]
DiNAQOR AG Announces Research Collaboration and License Agreement with UCL to Investigate Gene Therapies for Heart Failure
SAN FRANCISCO and PFÄFFIKON, Switzerland and LONDON, Jan. 13, 2020 /PRNewswire/ — DiNAQOR AG, a global gene therapy platform company, today announced a research collaboration and exclusive license agreement with UCL to develop novel gene therapies for the treatment of monogenic cardiomyopathies, diseases of the heart muscle that can lead to heart failure in children and adults. […]
Sequana Medical announces first-in-human data of Direct Sodium Removal (DSR) therapy published in Circulation
Positive pre-clinical and clinical proof-of-concept data of Sequana Medical’s innovative DSR therapy published in top tier peer-reviewed cardiovascular journal Data demonstrates potential for treatment of volume overload due to heart failure Ghent, BELGIUM – 10 January 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid […]
Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy
BOSTON and CARLSBAD, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today the initiation of the CARDIO-TTRansform Phase 3 cardiovascular outcomes study for AKCEA-TTR-LRx in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR cardiomyopathy). “The […]
JenaValve Transcatheter Aortic Valve Replacement (TAVR) System Designated by FDA as Breakthrough Device
JenaValve Pericardial TAVR System is the First Transcatheter Device to Achieve Breakthrough Device Designation; Prioritizes Premarket Approval Development Path for Severe Aortic Regurgitation Indication IRVINE, Calif.–(BUSINESS WIRE)–JenaValve Technology, Inc., developer and manufacturer of the JenaValve Pericardial transcatheter aortic valve replacement (TAVR) system for the treatment of aortic valve disease, announced […]
FAST BioMedical Announces Successful Completion of Multi-center Acute Congestive Heart Failure Trial in Germany
INDIANAPOLIS and BERLIN and BAD NAUHEIM, Germany, Jan. 9, 2020 /PRNewswire/ — FAST BioMedical announced the completion of the EMPAKT-CHF clinical trial at Charité – Universitätsmedizin Berlin and Kerckhoff Klinik in Bad Nauheim. The trial evaluated the impact of FAST BioMedical’s Blood Volume and Kidney Function measurement technology in patients with acute congestive heart failure and cardiorenal syndrome. This […]
FDA Confirms Non-Exempt Status of Medical Device but No Plans to Inform the Patients as Confirmed by Dr. Rajamannan in Press Conference at Most Sacred Heart of Jesus Cardiology and Valvular Institute
FDA confirms no plan to inform patients of non-exempt medical devices placed in 667 citizens. SHEBOYGAN, Wis., Jan. 9, 2020 /PRNewswire/ — Following recent reporting by Kaiser Health News that the FDA has lifted their exemption laws, Dr. Nalini Rajamannan a specialist for patients with valvular heart disease in Most Sacred Heart of Jesus Cardiology, […]
CHF Solutions Announces Presentation of Clinical Data with Aquadex FlexFlow® Highlighting Efficacy and Simplicity of Use In Treating Critical Care Patients
EDEN PRAIRIE, Minn., Jan. 08, 2020 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS) today announced results from an investigator-initiated retrospective analysis of utilization of the Aquadex FlexFlow aquapheresis system at Lenox Hill Hospital in New York City. The study was presented at the American Society of Nephrology’s Kidney Week in […]



